Guardant Health, Inc. (GH)
165.88
+2.89
(+1.77%)
USD |
NASDAQ |
Oct 15, 16:00
166.00
+0.12
(+0.07%)
After-Hours: 06:46
Guardant Health Research and Development Expense (Quarterly) : 96.53M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 96.53M |
| March 31, 2026 | 91.04M |
| December 31, 2025 | 98.26M |
| September 30, 2025 | 89.96M |
| June 30, 2025 | 87.45M |
| March 31, 2025 | 88.52M |
| December 31, 2024 | 93.54M |
| September 30, 2024 | 87.31M |
| June 30, 2024 | 83.10M |
| March 31, 2024 | 83.80M |
| December 31, 2023 | 89.20M |
| September 30, 2023 | 93.35M |
| June 30, 2023 | 89.86M |
| March 31, 2023 | 92.53M |
| December 31, 2022 | 104.00M |
| September 30, 2022 | 99.62M |
| June 30, 2022 | 85.26M |
| March 31, 2022 | 79.66M |
| December 31, 2021 | 73.02M |
| Date | Value |
|---|---|
| September 30, 2021 | 70.97M |
| June 30, 2021 | 63.72M |
| March 31, 2021 | 55.51M |
| December 31, 2020 | 40.28M |
| September 30, 2020 | 36.24M |
| June 30, 2020 | 36.32M |
| March 31, 2020 | 28.52M |
| December 31, 2019 | 25.88M |
| September 30, 2019 | 24.57M |
| June 30, 2019 | 19.53M |
| March 31, 2019 | 16.32M |
| December 31, 2018 | 16.65M |
| September 30, 2018 | 14.25M |
| June 30, 2018 | 11.55M |
| March 31, 2018 | 8.255M |
| December 31, 2017 | 8.12M |
| September 30, 2017 | 7.246M |
| June 30, 2017 | 5.494M |
| March 31, 2017 | 4.702M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Natera, Inc. | 228.07M |
| Quest Diagnostics, Inc. | -- |
| Labcorp Holdings, Inc. | -- |
| OPKO Health, Inc. | 33.17M |
| Psychemedics Corp. | -- |